Rockwell Medical Inc. (RMTI) Sees Unusually-High Trading Volume
Shares of Rockwell Medical Inc. (NASDAQ:RMTI) saw strong trading volume on Tuesday . 451,331 shares changed hands during mid-day trading, an increase of 87% from the previous session’s volume of 240,748 shares.The stock last traded at $7.13 and had previously closed at $7.51.
Separately, Zacks Investment Research upgraded Rockwell Medical from a “sell” rating to a “hold” rating in a research report on Friday, May 13th. Four analysts have rated the stock with a sell rating, three have given a hold rating and one has issued a buy rating to the company. Rockwell Medical has an average rating of “Hold” and an average price target of $10.17.
The firm’s 50 day moving average is $7.74 and its 200-day moving average is $7.82. The stock’s market cap is $372.53 million.
Rockwell Medical (NASDAQ:RMTI) last announced its quarterly earnings data on Monday, August 8th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by $0.01. During the same quarter in the prior year, the business posted ($0.05) earnings per share. The company earned $12.50 million during the quarter, compared to the consensus estimate of $13.86 million. The firm’s quarterly revenue was down 3.5% compared to the same quarter last year. Equities research analysts predict that Rockwell Medical Inc. will post ($0.26) EPS for the current fiscal year.
Rockwell Medical, Inc (Rockwell) is a biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis. The Company operates through the hemodialysis market segment, which involves the manufacture, sale and distribution of hemodialysis products to hemodialysis clinics, including pharmaceutical, dialysis concentrates, dialysis kits and other ancillary products used in the dialysis process.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.